ArticleLiver international : official journal of the International Association for the Study of the Liver2019
Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- Differential NMR Lipoprotein Profiles and Prediction of Insulin Resistance and Metabolic Syndrome by LP-IR Among Adult Chronic Hepatitis B Patients.Journal of clinical medicine · 2025Article
- [Research progress on the impact of metabolic associated fatty liver disease on viral activity, treatment response, and prognosis in patients with chronic hepatitis B: current status and prospects].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Hepatitis B Virus X Protein Upregulates SREBP2 to Modulate Autophagy in Hepatocellular Carcinoma.Cancer medicine · 2025Article
- Correlation between ultrasound-based hepatic steatosis grade and thyroid hormone levels.Gland surgery · 2025Article
- [Research progress of antiviral treatment for patients with chronic hepatitis B combined with metabolic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study.Journal of clinical medicine · 2024Article
- Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis.World journal of clinical cases · 2024Article
- Metabolic disorders and hepatitis: Insights from a Mendelian randomization study.World journal of gastrointestinal surgery · 2024Article
- Independent predictors for non-alcoholic fatty liver disease in patients with treatment-naïve chronic hepatitis B.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients.Frontiers in medicine · 2024Article
- Review
- Article
- Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection.iScience · 2023Article
- High HBV-DNA serum levels are associated with type 2 diabetes in adults with positive HBsAg: An observational study.Frontiers in endocrinology · 2023Observational
- Effect modification of hepatitis B viral load on the association between metabolic risk factors and hepatic steatosis.Translational gastroenterology and hepatology · 2023Article
- Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis.Heliyon · 2023Review
- Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort).Cannabis and cannabinoid research · 2022Article
- Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study.Medicina clinica · 2022Article
- Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study.Medicina clinica (English ed.) · 2022Article
- Hepatoprotective mechanism ofBioengineered · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsAlthough non-alcoholic fatty liver disease (NAFLD) has been studied extensively, the potential risk factors for NAFLD among chronic hepatitis B (CHB) patients have not been fully known.
methodsA population-based cohort of adult CHB patients without a history of alcohol drinking or NAFLD were recruited and followed up from October 2012 to January 2015 in Jiangsu province, China. Using Cox proportional hazards regression model, potential risk factors including viral and metabolic factors for NAFLD were evaluated.
resultsTwo thousand three hundred and ninety-three adult CHB patients (mean age 50.7 ± 13.2 years) were included in the cohort. With 4429 person-years of follow-up, 283 individuals progressed to NAFLD with an incidence rate of 63.89/1000 person-years. Overweight and obese CHB patients had an increased risk of NAFLD (overweight adjusted hazard ratio [HR], 3.10; 95% CI, 2.29-4.18; obese HR, 8.52; 95%CI, 5.93-12.25) compared to normal weight carriers. The incidence of NAFLD was associated with concurrent type 2 diabetes mellitus (DM) (HR, 1.88; 95%CI, 1.15-3.08). However, no associations between viral factors with NAFLD incidence rate were identified. In a subgroup of participants with concurrent type 2 DM, detectable HBV DNA levels were negatively associated with the development of NAFLD (HR, 0.37; 95%CI, 0.14-0.98). There was super-multiplicative interaction between BMI and gender with respect to incidence of NAFLD, with an ROR of 2.08 (95%CI, 1.02-4.23).
conclusionMetabolic factors play an important role in the presence of NAFLD among Chinese CHB patients. However, viral replication factors are not related to NAFLD except among those with concurrent type 2 DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.